Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 09, 2012 08:00 ET | Source: Laurantis Pharma OY

U.S. Patent Office Issues Patent to Laurantis for Cis-UCA as a Treatment for Bladder Cancer

TURKU, FINLAND--(Marketwire - Oct 9, 2012) - The United States Patent and Trademark Office has allowed a patent application by Laurantis Pharma Oy (Laurantis) for the use of cis-urocanic acid...
September 04, 2012 07:59 ET | Source: Laurantis Pharma OY

Laurantis Pharma Completes Funding Round for Research Program

BOSTON, MA and TURKU, FINLAND--(Marketwire - Sep 4, 2012) - Laurantis Pharma today announced successful completion of a funding round, which raised EUR 5.64 million (US$7.02 million). A...
August 01, 2012 08:00 ET | Source: Laurantis Pharma Oy

U.S. Patent Office Allows Laurantis Application for Treatment of Skin Inflammation

TURKU, FINLAND--(Marketwire - Aug 1, 2012) - The United States Patent and Trademark Office has allowed a patent application by Laurantis Pharma Oy (Laurantis) as it pertains to the topical...
June 28, 2012 10:03 ET | Source: Laurantis Pharma OY

Investigational Cis-urocanic Acid Eye Drops for Dry Eye Syndrome Well Tolerated, in Phase 1 Clinical Study

TURKU, FINLAND--(Marketwire - Jun 28, 2012) - Laurantis Pharma today announced that it has completed a phase 1 clinical study with its Cis-urocanic acid eye drops. The objective of the study was to...
June 26, 2012 07:00 ET | Source: National Association of People with AIDS

MEDIA ADVISORY: Speaker Lineup Unveiled for National HIV Testing Day Press Conference; Representatives, HIV Advocates to Take the Test, Spotlight Ryan White Funding, Affordable Care Act and More

WASHINGTON, DC--(Marketwire - Jun 26, 2012) - The National Association of People with AIDS (NAPWA) and OraSure Technologies, Inc. (NASDAQ: OSUR) announced an expected lineup of speakers who...
June 07, 2012 07:01 ET | Source: Bionor Pharma

International Patent Application Submitted for the Therapeutic and Potentially Preventive Vaccine Vacc-HIV, Combining Bionor's Vacc-4x and Vacc-C5

OSLO, NORWAY--(Marketwire - Jun 7, 2012) - Bionor Pharma ASA (OSLO: BIONOR) announced today that it has initiated the international patent process for protection of the Company's peptide vaccine...
June 07, 2012 07:00 ET | Source: Bionor Pharma

International Patent Application Submitted Covering Vaccines for Influenza (Universal Vaccine), Hepatitis C, Cytomegalovirus and Human Papillomavirus

OSLO, NORWAY--(Marketwire - Jun 7, 2012) - Bionor Pharma ASA (OSLO: BIONOR) News Summary The new patent filed 6 June aims to strengthen the Company's general protection of its...
May 29, 2012 11:22 ET | Source: Bionor Pharma

First Human Clinical Study of HIV Vaccine Vacc-C5 Approved to Begin

OSLO, NORWAY--(Marketwire - May 29, 2012) - Bionor Pharma ASA (OSLO: BIONOR) News Summary Open, clinical study, dose escalating, phase I/II, with Bionor...
May 11, 2012 08:52 ET | Source: Bionor Pharma

Bionor Pharma's Shareholders Voted Industry Experts Steen Kroyer, Jerry Zeldis and Benedicte Fossum to Its Board of Directors at Annual General Meeting

OSLO, NORWAY--(Marketwire - May 11, 2012) - Bionor Pharma ASA (OSLO: BIONOR) announced today unanimously shareholder approval for new and re-elected Board members to the Board of Directors, and...
May 10, 2012 06:47 ET | Source: Bionor Pharma

Successful Immunization and Safety Documented in Nasal Administration Study of the HIV Vaccine Vacc-4x Together With Endocine

OSLO, NORWAY--(Marketwire - May 10, 2012) - Bionor Pharma (OSLO: BIONOR) News Summary Vaccine related immune responses found in HIV patients given Vacc-4x...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right